Equities researchers at Stephens initiated coverage on shares of Catalent (NYSE:CTLT) in a note issued to investors on Thursday, October 17th, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $56.00 price target on the stock. Stephens’ price objective would indicate a potential upside of 13.09% from the stock’s current price.
Several other brokerages also recently issued reports on CTLT. UBS Group raised their price objective on shares of Catalent to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. ValuEngine downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Jefferies Financial Group upgraded shares of Catalent from a “hold” rating to a “buy” rating and lifted their price target for the stock from $50.00 to $62.00 in a research note on Friday, June 21st. Robert W. Baird lifted their price target on shares of Catalent from $50.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Finally, Morgan Stanley lifted their price target on shares of Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $56.25.
CTLT stock traded up $0.27 during mid-day trading on Thursday, reaching $49.52. 467,188 shares of the stock traded hands, compared to its average volume of 806,017. The company has a current ratio of 2.06, a quick ratio of 1.70 and a debt-to-equity ratio of 2.74. Catalent has a 52-week low of $29.23 and a 52-week high of $58.38. The company has a market cap of $7.38 billion, a P/E ratio of 30.57, a P/E/G ratio of 2.47 and a beta of 1.69. The stock’s fifty day moving average is $49.09 and its 200-day moving average is $50.57.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.07. The company had revenue of $664.70 million during the quarter, compared to analyst estimates of $634.87 million. Catalent had a net margin of 5.77% and a return on equity of 16.87%. The business’s quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.28 earnings per share. Equities research analysts expect that Catalent will post 1.81 earnings per share for the current year.
In other Catalent news, CEO John R. Chiminski sold 97,043 shares of Catalent stock in a transaction on Monday, October 7th. The stock was sold at an average price of $48.84, for a total transaction of $4,739,580.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gregory T. Lucier purchased 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was acquired at an average cost of $51.64 per share, with a total value of $103,280.00. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Evolution Wealth Advisors LLC bought a new position in shares of Catalent in the second quarter valued at about $32,000. Advisory Services Network LLC increased its position in Catalent by 115.5% in the second quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock worth $39,000 after purchasing an additional 395 shares during the period. Quest Capital Management Inc. ADV acquired a new stake in Catalent in the third quarter worth about $53,000. Bamco Inc. NY acquired a new stake in Catalent in the second quarter worth about $81,000. Finally, Atria Investments LLC acquired a new stake in Catalent in the second quarter worth about $296,000.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: Forex
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.